Source : ITPC EECA Against the backdrop of a recent press release from Gilead announcing the signing of a voluntary license for the new drug lenacapavir, ViiV Healthcare has announced an increase in
بيان صحفي إعلان شركة جيلياد عن حصول ستة مصنعين للأدوية الجنيسة على تراخيص طوعية لإنتاج ليناكابافير – وهو عقار قابل للحقن مرتين في السنة للوقاية من فيروس نقص المناعة البشرية وعلاجه المحتمل –
Communiqué de presse – 4 Octobre 2024 Gilead annonce que six fabricants de génériques ont obtenu des licencesvolontaires pour produire le lenacapavir, un injectable révolutionnaire pour laprévention et le traitement potentiel du VIH,
Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant
Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies
